简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

据周日报道,IDEAYA公司已选定IDE101作为候选药物,该药物是一种针对实体肿瘤中CDKN2A基因缺陷的双重CDK抑制剂。该药物的上市许可申请计划于2027年第一季度提交。

2026-11-16 13:19

  • Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892
  • CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of all solid tumors, including ~70% of pancreatic cancer
  • IDE101's preclinical profile, including combination results with inhibitors of PRMT5 and pan-RAS, will be summarized at IDEAYA's London R&D Day
  • IND-enabling studies underway to support an IND filing in H1 2027

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。